Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 4 1

Status

Unknown 4Terminated 1Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 6

Conditions

Ovarian Neoplasms 45Breast Neoplasms 39Triple Negative Breast Neoplasms 19Prostatic Neoplasms 17Neoplasms 13Fallopian Tube Neoplasms 13Endometrial Neoplasms 12Recurrence 8Pancreatic Neoplasms 8Neoplasm Metastasis 8Squamous Cell Carcinoma of Head and Neck 7Small Cell Lung Carcinoma 7Lung Neoplasms 6Carcinoma, Ovarian Epithelial 6Glioma 5Glioblastoma 5Carcinoma, Renal Cell 5Uterine Cervical Neoplasms 4Sarcoma 4Carcinoma, Squamous Cell 4Carcinoma, Non-Small-Cell Lung 4Advanced Breast Cancer 4Stomach Neoplasms 3Solid Tumor 3Melanoma 3Head and Neck Neoplasms 3Fanconi Anemia, Complementation Group D1 3Uveal Melanoma 2Uterine Neoplasms 2Urinary Bladder Neoplasms 2

Interventions

Carboplatin 44Paclitaxel 41Cyclophosphamide 21Topotecan 19Cisplatin 18Peripheral Blood Stem Cell Transplantation 15Filgrastim 15Docetaxel 15Gemcitabine 13Bevacizumab 13liposomal doxorubicin 11Hyperthermic Intraperitoneal Chemotherapy 11sargramostim 9Therapeutics 8Immunohistochemistry 8Psychiatric Rehabilitation 7Drug Therapy 7Amifostine 7pembrolizumab 6olaparib 6Taxes 6Surveys and Questionnaires 6Melphalan 6Flow Cytometry 6Early Intervention, Educational 6Chemotherapy, Adjuvant 6niraparib 5denileukin diftitox 5Surgical Procedures, Operative 5Immunoenzyme Techniques 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Ovarian Epithelial × olaparib × Clear all
NCT06121401 2025-09-17

IOLANTHE

Mario Negri Institute for Pharmacological Research

Phase 4 Active not recruiting
190 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT04377087 2024-08-20

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

University of Pittsburgh

Phase 2 Terminated
3 enrolled 9 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT04015739 2022-08-17

BOLD

ARCAGY/ GINECO GROUP

Phase 2 Unknown
74 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Recurrence

NCT05158062 2022-04-26

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Saitama Medical University International Medical Center

Phase 2 Unknown
35 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT02822157 2021-01-29

CLIO

Universitaire Ziekenhuizen KU Leuven

Phase 2 Unknown
160 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT04566952 2020-10-30

ANLOLA

Jiangsu Cancer Institute & Hospital

Phase 2 Unknown
68 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Adnexal Diseases, Carcinoma, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡